OSCR
Oscar Health, Inc.
OSCR has the edge over RMTI overall, supported by stronger fundamentals and stronger modeled upside.
RMTI
Rockwell Medical, Inc.
RMTI has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RMTI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Strong |
RMTI's balance sheet is currently strong, and its revenue and cash flow are stable, but its profitability is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
RMTI PE Valuation
RMTI has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over RMTI on the outlook, with more favorable profitability expectations.
RMTI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect RMTI's losses to shrink, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over RMTI on earnings quality, reporting a profit while its opponent remains loss making.
RMTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.43 | +$0.17 |
| Q2 2026 | -$1.34 | -$0.64 |
| Q1 2026 | -$1.50 | -$1.40 |
| Q4 2025 | -$1.50 | -$1.20 |
| Q3 2025 | -$1.60 | -$1.16 |
| Q2 2025 | -$0.70 | +$0.84 |
| Q1 2025 | -$0.10 | +$3.34 |
| Q4 2024 | -$0.30 | +$3.54 |
RMTI is still losing money, but far less than before: $1.43 per share over the past year, against $61.60 at its worst in late 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RMTI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over RMTI on profitability, with a higher operating margin.
RMTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.1M | +20% |
| Q2 2026 | $17.8M | +11% |
| Q1 2026 | $17.3M | -8.3% |
| Q4 2025 | $18.3M | -26% |
| Q3 2025 | $15.9M | -44% |
| Q2 2025 | $16.1M | -38% |
| Q1 2025 | $18.9M | -17% |
| Q4 2024 | $24.7M | +12% |
RMTI's revenue is recovering but still below its 2024 peak: $19M last quarter, up 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12% | -1.7 points |
| Q2 2026 | -6% | +2.4 points |
| Q1 2026 | -8.5% | -1.3 points |
| Q4 2025 | -2.2% | -0.1 points |
| Q3 2025 | -10% | -17 points |
| Q2 2025 | -8.4% | -10 points |
| Q1 2025 | -7.2% | -1.4 points |
| Q4 2024 | -2.1% | +0.4 points |
RMTI's operating margin was −12% last quarter, down 1.7 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
RMTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.2M | -$712K |
| Q2 2026 | $1.5M | -13% |
| Q1 2026 | -$592K | +$3M |
| Q4 2025 | $2.2M | +369% |
| Q2 2025 | $1.7M | +17% |
| Q1 2025 | -$3.6M | -$1.2M |
| Q4 2024 | $470K | +$513K |
| Q2 2024 | $1.4M | +$3.2M |
RMTI's free cash flow has turned positive after six years mostly in the red: $828,000 over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RMTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +13.4K shares |
| 1 year | +10% | +369K shares |
| 3 years | +115% | +2.1M shares |
| 5 years | +367% | +3.1M shares |
| Available history | +617% | +3.4M shares |
RMTI has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
RMTI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | -4.3x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q4 2024 | -2.6x | Net Cash |
| Q3 2024 | -1.4x | Net Cash |
RMTI has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RMTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.4 | Neutral |
| Stochastic | 34.5 | Neutral |
RMTI's weekly RSI is 46 (neutral) and its Stochastic is 34 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RMTI PE vs Healthcare Sector
RMTI has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over RMTI on trend strength, trading above more of its moving averages.
RMTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.68 | 3.9% below |
| 20 week MA | $7.37 | 0.1% above |
| 50 week MA | $8.25 | 11% below |
| 100 week MA | $10.8 | 32% below |
| 200 week MA | $17.0 | 57% below |
RMTI's trend is mixed: it's above one of its five weekly moving averages, and 57% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RMTI on returns for 2026, with the stronger performance.
RMTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $258.5 | $111.1 | -57% |
| 2021 | $111.1 | $44.0 | -60% |
| 2022 | $44.0 | $9.70 | -78% |
| 2023 | $9.70 | $18.9 | +95% |
| 2024 | $18.9 | $21.4 | +13% |
| 2025 | $21.4 | $8.65 | -60% |
| 2026 YTD | $8.65 | $7.38 | -15% |
RMTI has finished lower in four of the last six years. It's down 15% so far in 2026.